CLINICAL TRIAL: PHASE I/II MULTICENTER,OPEN LABEL,NONCOMPARITIVE STUDY OF HIV AF

$19,244M01FY2009RRNIH

State University New York Stony Brook, Stony Brook NY

Investigators

Linked publications & trials

Paper 32323119 Paper 32150012 Paper 32101469 Paper 31730370 Paper 31274822 Paper 30768420 Paper 30592635 Paper 29897394 Paper 29746629 Paper 29602328 Paper 29205487 Paper 28872573 Paper 28290253 Paper 28212067 Paper 28100465 Paper 27920072 Paper 27765998 Paper 27348211 Paper 27238065 Paper 27227692 Paper 26786551 Paper 26745211 Paper 26696036 Paper 26538055 Paper 26504369 Paper 26478104 Paper 26476140 Paper 26259142 Paper 26230481 Paper 26029946 Paper 25897637 Paper 25894709 Paper 25885012 Paper 25885010 Paper 25572087 Paper 25346863 Paper 25151418 Paper 24828086 Paper 24680565 Paper 24652485 Paper 24573133 Paper 24535626 Paper 24447618 Paper 24444174 Paper 24443797 Paper 24342385 Paper 24290463 Paper 24290461 Paper 24198441 Paper 24072721 Paper 24002093 Paper 23922399 Paper 23898179 Paper 23894310 Paper 23880378 Paper 23823904 Paper 23799848 Paper 23786471 Paper 23784506 Paper 23751863 Paper 23714307 Paper 23696790 Paper 23475824 Paper 23446956 Paper 23407917 Paper 23398760 Paper 23368788 Paper 23334266 Paper 23247823 Paper 23205491 Paper 23192743 Paper 23128922 Paper 23123360 Paper 23037875 Paper 22999012 Paper 22948232 Paper 22947993 Paper 22933542 Paper 22930669 Paper 22924826 Paper 22862680 Paper 22775285 Paper 22674411 Paper 22651977 Paper 22409304 Paper 22378035 Paper 22349917 Paper 22267714 Paper 22183935 Paper 22117165 Paper 22098260 Paper 22062194 Paper 21999378 Paper 21895650 Paper 21859196 Paper 21683173 Paper 21606541 Paper 21603099 Paper 21595516 Paper 21567663

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 1. In Stage I, to evaluate the short term safety and tolerability of raltegravir, in HIV infected children and adolescents, added to an initial stable background therapy* which will then be optimized in children and adolescents in the age groups of =2 to <6, =6 to <12 and =12 to <19 years.

View original record on NIH RePORTER →